NeoGenomics, Inc. (NEO) return on equity (ROE)

Return on equity · fiscal 2025
-12.9%

NeoGenomics, Inc. (NEO) earned a return on equity of -12.9% in fiscal 2025 (the year ended December 31, 2025). That is 4.2 percentage points lower than the -8.7% of fiscal 2024. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-12.9%
Change on fiscal 2024
−4.2 pts
Highest on record
9.4%fiscal 2013
Lowest on record
-105.4%fiscal 2010
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

NeoGenomics, Inc. return on equity (ROE), in more detail

Across the 16 fiscal years on record (2010–2025), the highest was 9.4% in fiscal 2013 and the lowest -105.4% in fiscal 2010. The fiscal 2025 figure is higher than in 20% of the 15 earlier fiscal years on record, whose median is -0.8%.

History · 16 fiscal years

Return on equity by fiscal year

NeoGenomics, Inc. return on equity (ROE), year by year

NeoGenomics, Inc. (NEO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-12.9% 4.2 pts down
2024-8.7% 0.6 pts up
2023-9.3% 5.1 pts up
2022-14.5% 13.7 pts down
2021-0.8% 1.4 pts down
20200.6% 1.0 pts down
20191.6% 0.8 pts up
20180.8% 1.1 pts up
2017-0.2% 3.6 pts up
2016-3.8% 2.6 pts down
2015-1.2% 3.1 pts down
20141.9% 7.5 pts down
20139.4% 8.7 pts up
20120.7% 20.7 pts up
2011-20.0% 85.4 pts up
2010-105.4%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on NEO

NeoGenomics, Inc., figure by figure

NeoGenomics, Inc. (NEO) overview: price, valuation and scorecard

NeoGenomics, Inc. return on equity (ROE): questions and answers

What is NeoGenomics, Inc.'s return on equity?

NeoGenomics, Inc. (NEO) earned a return on equity of -12.9% in fiscal 2025 (the year ended December 31, 2025). That is 4.2 percentage points lower than the -8.7% of fiscal 2024.

Is NeoGenomics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 20% of the 15 earlier fiscal years on record, whose median is -0.8%.

What are the highest and lowest return on equity figures on record for NeoGenomics, Inc.?

Across the 16 fiscal years on record (2010–2025), the highest was 9.4% in fiscal 2013 and the lowest -105.4% in fiscal 2010.

How is NeoGenomics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For NeoGenomics, Inc. it is on record here for 16 fiscal years, 2010 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “NeoGenomics, Inc. (NEO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/NEO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.